In vitro and in vivo analysis of the human cyp3a5 promoter

被引：0
|
作者：
Nem, D. [1 ]
Qiu, H. [1 ]
Nestler, S. [1 ]
Goedtel-Armbrust, U. [1 ]
Wojnowski, L. [1 ]
机构：
[1] Univ Med Mainz, Mainz, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2010年 / 381卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：88 / 88
页数：1
相关论文
共 50 条
  • [21] PharmVar GeneFocus: CYP3A5
    Rodriguez-Antona, Cristina
    Savieo, Jessica L.
    Lauschke, Volker M.
    Sangkuhl, Katrin
    Drogemoller, Britt, I
    Wang, Danxin
    Schaik, Ron N. H.
    Gilep, Andrei A.
    Peter, Arul P.
    Boone, Erin C.
    Ramey, Bronwyn E.
    Klein, Teri E.
    Whirl-Carrillo, Michelle
    Pratt, Victoria M.
    Gaedigk, Andrea
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 112 (06) : 1159 - 1171
  • [22] Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5
    Soars, M. G.
    Grime, K.
    Riley, R. J.
    XENOBIOTICA, 2006, 36 (04) : 287 - 299
  • [23] Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro
    Amundsen, Rune
    Asberg, Anders
    Ohm, Ingrid Kristine
    Christensen, Hege
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 655 - 661
  • [24] CHARACTERIZATION OF INDIVIDUAL DIFFERENCES IN CYP3A5 ACTIVITY USING A CYP3A5-SELECTIVE MARKER REACTION IN VITRO
    Jackson, Klarissa
    Abouda, Arsany
    Wines, Kahari
    DRUG METABOLISM AND PHARMACOKINETICS, 2019, 34 (01) : S25 - S26
  • [25] Effect of CYP3A5 genotype on the relationship between hepatic CYP3A activity and CYP3A4 and CYP3A5 mRNA expression
    Kolwankar, D
    Ho, H
    Ethell, B
    Vuppalanchi, R
    Marri, SR
    Wrighton, SA
    Jones, DR
    Hall, SD
    DRUG METABOLISM REVIEWS, 2004, 36 : 118 - 118
  • [26] Differential regulation of human CYP3A4 and CYP3A5 genes in lung cells
    Biggs, JS
    Yost, GS
    DRUG METABOLISM REVIEWS, 2002, 34 : 26 - 26
  • [27] Regulation of human CYP3A4 and CYP3A5 genes in lung cells.
    Biggs, JS
    Raunio, H
    Hakkola, J
    Pelkonen, O
    Yost, GS
    FASEB JOURNAL, 2002, 16 (04): : A180 - A180
  • [28] CYP3A4 and CYP3A5 genotyping by pyrosequencing
    Garsa, AA
    McLeod, HL
    Marsh, S
    BMC MEDICAL GENETICS, 2005, 6
  • [29] USE OF THE CYP3A4 SELECTIVE INHIBITOR CYP3CIDE IN CYP3A5 GENOTYPED CRYOPRESERVED HUMAN HEPATOCYTES TO EXPLORE THE INDIVIDUAL CONTRIBUTION OF CYP3A4 AND CYP3A5 IN DRUG METABOLISM
    Heyward, Scott
    Schultz, Rachel N. V.
    Dennell, Stephen
    DRUG METABOLISM REVIEWS, 2014, 45 : 135 - 136
  • [30] Importance of genotyping CYP3A5*6 and CYP3A5*7 alleles in determining the tacrolimus daily dose
    Fonrose, X.
    Roustit, M.
    Broly, F.
    Rey, I.
    Malvezzi, P.
    Janbon, B.
    Boyle, F.
    Hardy, G.
    Lunardi, J.
    Bessard, G.
    Stanke-Labesque, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2008, 22 : 56 - 56
12345